bioRxiv Science⌕ Search

bioRxiv · 10.1101/2024.04.20.590429

A Novel Pan-Proteome Array for High-Throughput Profiling of the Humoral Response to Treponema pallidum subsp. pallidum: a Pre-Clinical Study

Abstract

BackgroundGiven the resurgence of syphilis, research endeavors to improve current assays for serological diagnosis and management of this disease are a priority. A proteome-scale platform for high-throughput profiling of the humoral response to Treponema pallidum (T. pallidum) proteins during infection could identify antigens suitable to ameliorate the performance and capabilities of treponemal tests (TTs), which may require weeks to become positive following infection, cannot distinguish between active and previously treated infections, or assess treatment response. Additionally, because infection-induced immunity is partially protective, profiling the response to T. pallidum outer membrane proteins (OMPs) could help select vaccine candidates. MethodsWe developed a pan-proteome array (PPA) based on the Nichols and SS14 strain complete proteomes and used it to define the IgM and IgG humoral response to 1,009 T. pallidum proteins in sera collected longitudinally from long-term infected rabbits, and from rabbits that were infected, treated, and re-infected. FindingsApproximately a third of the pathogens proteome was recognized in infected animals, with a marked IgG response detectable between day-10 and day-20 post-infection. We found early, gradual, and late IgG kinetic profiles, strain-dependent differences in humoral reactivity, and post-treatment fluctuation in reactivity for several antigens. Very few antigens elicited an IgM response. Several OMPs were significantly and differentially recognized, but few elicited a robust response. InterpretationThe PPA allowed the identification of antigens that could facilitate early diagnosis and of a core set of OMP that could explain protection upon re-infection. No antigen appeared suitable to monitor treatment response. FundingNIH SBIR-R43AI149804 RESEARCH IN CONTEXTO_ST_ABSEvidence before this studyC_ST_ABSIn April 2024, we searched the PubMed database for articles on preclinical studies using high throughput proteome arrays containing at least 10% of the predicted T. pallidum proteome that aimed at identifying antibody reactivity to T. pallidum antigens during experimental syphilis infection. We could retrieve only one manuscript. In this work, an array containing the T. pallidum partial proteome as annotated in the first sequenced Nichols strain genome (GCA_000008605.1) in 1998 was assembled using recombinant antigens expressed in Escherichia coli (E. coli). The resulting array was probed using pooled sera from three rabbits infected with the Nichols stain of T. pallidum, attained from infected animals at five time points following intratesticular infection. The small number of reactive antigens (n = 106) identified in this early study was likely to be an incomplete set of all antigens recognized during infection because not all the predicted targets in the T. pallidum proteome were successfully expressed and tested. In retrospect, additional limitations of the study included an initial suboptimal annotation of the Nichols genome used to define the pathogens proteome, which has now changed with the availability of a re-sequenced Nichols strain genome devoid of sequencing errors that affected the initial annotation process, and the refinement of bioinformatic pipelines for the identification of open reading frames (ORFs). Furthermore (as acknowledged by the authors), the possible presence of amplification errors in their expression clones might have affected the sequence of some protein targets and antibody binding to the targets. As a result, some of the T. pallidum antigens known to elicit a robust humoral response during experimental infection were not detected in this antigenic screen. Lastly, employing only the Nichols strain in this early study did not consider that a significant portion of the circulating syphilis strains belong to the SS14 clade of T. pallidum. Added value of this studyThis novel PPA, combined with a more robust experiential design than ever reported, allowed us to overcome most of the limitations associated with the study mentioned above, as we were able to a) use the most recent annotations for the selected T. pallidum strains based on accurate genome sequences, b) print the pathogens virtually complete proteome in the study array, c) analyze individual sera to account for rabbit-to-rabbit variability in the humoral response to infection rather than pooled sera, d) detect both IgM and IgG over 10 or 20 timepoints, depending on the experimental design, e) obtain information on how the humoral response evolved upon treatment and re-infection and, finally, f) evaluate all of the above in animals infected with two T. pallidum strains whose genetic background is representative of the two currently circulating clades of the syphilis agent. Implications of all the available evidenceOur study provides new and more comprehensive data on how humoral immunity for two classes of antibodies develops during infection and how it evolves in response to treatment and re-infection. The analysis of sera collected at tightly spaced time points post-inoculation and for an extensive period post-infection provides a wealth of information to improve the diagnostic performance of existing tests detecting treponemal antigens. The analysis of differential immunity specific to the pathogens putative OMPs provides a rationale for vaccine candidate selection.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

Campo, J. J., Romeis, E., Oberai, A., Pablo, J., Hung, C., Teng, A., Shandling, A. D., Phan, A., Haynes, A., Giacani, L.. 2024-04-21. A Novel Pan-Proteome Array for High-Throughput Profiling of the Humoral Response to Treponema pallidum subsp. pallidum: a Pre-Clinical Study. https://doi.org/10.1101/2024.04.20.590429

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related preprints

A conserved cysteine-histidine-glutamate metal site identifies DUF501 (Rv1025), an essential uncharacterised protein family of Mycobacterium tuberculosis, as a candidate metalloenzyme and drug target

A substantial fraction of the Mycobacterium tuberculosis proteome remains functionally uncharacterised. Rv1025, a 155-residue protein carrying the domain of unknown function DUF501 (Pfam PF04417), is essential by transposon mutagenesis and vulnerable by CRISPR interference, an attractive but neglected drug target, yet has never been functionally described. The family (4,370 proteins, no Gene Ontology term, no solved structure) is uncharacterised across all organisms and essential in three Actinobacterial genera. A Foldseek search of the AlphaFold model against complete structural databases finds no significant homolog, indicating a novel fold. The operon eno-divIC-Rv1025-ppx2 is conserved across the Actinobacteria phylum, yet AlphaFold-Multimer finds no direct complex between Rv1025 and its neighbour DivIC. Instead, conservation across 8,700 homologous sequences reveals a near-invariant Cys113-His115-Glu59 cluster forming a pocket. Holo AlphaFold3 predictions with Zn, Fe and Mn confidently place a divalent metal on this triad at 2.25-2.47 A; mutating the triad relocates the metal, and an independent backbone-geometry predictor recovers the same site, confirming specificity. The triad is universal across the family: present in all 1,472 near-complete bacterial sequences of the Pfam alignment, with no non-conservative substitution among the 2,228 sequences examined, a defining feature of bacterial DUF501 rather than a mycobacterial peculiarity. We propose that DUF501 is a metal-binding protein and candidate metalloenzyme, the first functional hypothesis for this family, whose conserved, essential metal pocket is a promising drug target. As the predictions build on a conservation-defined site within a fully computational study, they are supportive rather than proof of metal occupancy and warrant experimental validation.

microbiology↗

Mycoplasmal endosymbionts of Trichomonas vaginalis are associated with reduced risk for Chlamydia trachomatis endometrial infection in asymptomatic, coinfected, women.

Trichomonas vaginalis is a protozoan parasite that causes trichomoniasis, the most common curable non-viral sexually transmitted infection, and Chlamydia trachomatis is a bacterial pathogen that can ascend to the upper genital tract and cause pelvic inflammatory disease, infertility, and ectopic pregnancy. T. vaginalis harbors bacterial endosymbionts, including Candidatus Malacoplasma girerdii, an obligate symbiont, and Metamycoplasma hominis, which can live freely or symbiotically. In a 16S rRNA sequencing study of the cervicovaginal microbiome of women at high risk for chlamydial infection, Ca. M. girerdii abundance was one of 13 features predicting lack of chlamydial spread to the endometrium, despite no direct association between T. vaginalis infection and reduced chlamydial ascension. Investigating the relationship between these microorganisms further, we found that T. vaginalis vaginal abundance correlated positively with chlamydial burden in women whose infection was confined to the cervix, while a nonsignificant inverse relationship was seen in women with endometrial spread. Among participants with high chlamydial burden, Ca. M. girerdii was detected exclusively in women without endometrial infection. Both endosymbionts trended toward more frequent detection, and higher abundance, in coinfected women without endometrial spread, while M. hominis abundance correlated strongly with T. vaginalis burden in this group. These findings suggest that mycoplasmal endosymbionts of T. vaginalis, rather than T. vaginalis itself, are microbial factors limiting chlamydial ascension, and point to a three-way interaction between parasite, endosymbiont, and bacterial pathogen that shapes upper genital tract C. trachomatis infection risk.

microbiology↗

Understanding the physiological alterations of Vibrio cholerae upon exposure to L-ascorbic acid

The scourge of cholera remains a major global public health threat. It affects up to 4 million people worldwide and causes tens of thousands of deaths each year. The disease is experiencing a concerning resurgence in many parts of Africa, the Middle East, and Asia. To effectively tackle cholera and circumvent rising antimicrobial resistance, targeted biological and preventive approaches, complementing traditional rehydration, are urgently needed. In this regard, our group has demonstrated the efficacy of L-ascorbic acid in controlling the growth and pathogenesis of Vibrio cholerae in vitro. The present work further provides a mechanistic elucidation of the L-ascorbic acid-mediated physiological changes in V. cholerae and also bolsters such a non-antibiotic approach to control cholera.

microbiology↗